Syros Pharmaceuticals Inc (OQ:SYRS)

Oct 09, 2020 07:30 am ET
Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing dose escalation portion of its Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with select solid tumors. The data will be presented in a poster session at the 32nd EORTC-NCI-AACR Symposium, taking place virtually October 24-25, 2020, and will include data on safety, pharmacokinetics and pharmacodynamics.
Sep 10, 2020 08:30 am ET
Syros Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Cantor Virtual Global Healthcare Conference. Details are as follows:
Sep 09, 2020 08:31 am ET
Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S. Gail Eckhardt, M.D., to the Company’s Board of Directors. Dr. Eckhardt is a highly respected oncologist and a leader in targeted oncology drug development.
Aug 06, 2020 07:31 am ET
Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and upcoming events.
Aug 05, 2020 09:09 am ET
Syros Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as follows:
Jul 30, 2020 08:30 am ET
Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 6, 2020 to report its second quarter 2020 financial results and provide a corporate update.
Jul 07, 2020 08:00 am ET
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source. ...
Jun 17, 2020 08:00 am ET
Syros Announces Change to Presentation Time at JMP Securities Hematology and Oncology Forum
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a change to its presentation time at the upcoming JMP Securities Hematology and Oncology Forum. Updated details are as follows:
Jun 11, 2020 08:31 am ET
Syros to Present Virtually at JMP Securities Hematology and Oncology Forum
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows:
May 29, 2020 08:01 am ET
Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data show that SY-5609 inhibits tumor growth, including inducing sustained regressions, at well-tolerated doses in colorectal cancer models, supporting the inclusion of colorectal cancer patients in Syros’ ongoing Phase 1 clinical trial. These data were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Progr
May 28, 2020 08:00 am ET
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
CAMBRIDGE, Mass., May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity. ...
May 13, 2020 05:01 pm ET
Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in models of colorectal cancer. These data will be presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) taking place May 29-31. Syros will also present on the design of its ongoing Phase 1 trial of SY-5609 at ASCO20.
May 07, 2020 07:30 am ET
Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2020 and provided an update on recent accomplishments and upcoming events.
Apr 30, 2020 08:30 am ET
Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a corporate update.
Mar 05, 2020 07:30 am ET
Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended December 31, 2019, and provided an update on recent accomplishments and upcoming events.
Feb 27, 2020 08:00 am ET
Syros to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results and provide a corporate update.
Feb 24, 2020 08:00 am ET
Syros to Present at Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences:
Feb 13, 2020 08:00 am ET
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of a $60 million senior secured loan facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare service companies.
Jan 29, 2020 08:31 am ET
Syros Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition to Discover and Develop New Medicines for Difficult-to-Treat Cancers
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data showing that inhibiting cyclin-dependent kinase 7 (CDK7) results in different transcriptional effects than inhibiting cyclin-dependent kinase 12 (CDK12), pointing to distinct therapeutic opportunities to benefit patients with difficult-to-treat cancers. Building on its leadership in gene control, Syros also described new methods for identifying essential genes and transcriptional dependencies in cancer that could serve as potential drug targe
Jan 28, 2020 08:31 am ET
Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. The trial is enrolling patients with advanced breast, colorectal, lung or ovarian cancer, or with solid tumors of any histology that harbor Rb pathway alterations.
Jan 12, 2020 09:00 am ET
Syros Announces Strategic Priorities and Expected Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.
Dec 20, 2019 08:01 am ET
Syros Announces Appointment of Mark Alles to Its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company’s Board of Directors. Mr. Alles is a recognized biopharmaceutical executive with a proven record of building successful global oncology organizations and commercializing innovative therapies over his 30-year career.
Dec 18, 2019 07:15 am ET
GBT Secures $150 Million Non-Dilutive Term Loan Financing
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered into a $150 million loan agreement with funds managed by Pharmakon Advisors LP, a leading global life sciences investment firm and manager of the BioPharma...
Dec 18, 2019 07:00 am ET
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) today announced that they have entered into a collaboration to discover, develop and commercialize novel therapies for sickle cell disease (SCD) and...
Dec 08, 2019 08:00 am ET
Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X (NFIX), using its gene control platform. The finding sheds light on how the gamma-globin gene, which leads to the production of fetal hemoglobin, is controlled and points to new potential targets for therapeutic intervention in sickle cell disease. These data will be presented in an oral presentation tomorrow at the 61st American Society of Hematology (ASH) Annual Meeting a
Nov 26, 2019 08:31 am ET
Syros to Present at Piper Jaffray 31st Annual Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference. Details are as follows:
Nov 19, 2019 07:01 am ET
Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in triple-negative breast cancer (TNBC) in a poster presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS), taking place December 10-14 in San Antonio, Texas.
Nov 12, 2019 08:00 am ET
Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2019, and provided an update on recent accomplishments and upcoming events.
Nov 06, 2019 09:01 am ET
Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel fetal hemoglobin repressor in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting taking place December 7-10 in Orlando, Florida. The finding, which is part of Syros’ broader drug discovery effort in sickle cell disease, will also be highlighted in an ASH press briefing.
Nov 05, 2019 08:30 am ET
Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update.
Oct 29, 2019 04:01 pm ET
Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today presented new preclinical data for SY-5609, its highly-selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data demonstrate that SY-5609 induces deep and sustained anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors at doses below the maximum tolerated dose (MTD). These data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Oct 24, 2019 08:31 am ET
Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newl
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that updated clinical data from its ongoing Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine, continue to demonstrate high complete response rates, rapid onset of action and a favorable tolerability profile in a genomically defined subset of newly diagnosed acute myeloid leukemia (AML) patients who are not suitable candidates for standard intensive chemotherapy. These data
Oct 17, 2019 07:00 am ET
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its portfolio of selective cyclin-dependent kinase 7 (CDK7) inhibitors. The Company has decided to prioritize the development of its highly selective and potent oral CDK7 inhibitor, SY-5609, and to discontinue further development of SY-1365, its intravenous (IV) CDK7 inhibitor. Syros expects to initiate a Phase 1 clinical trial of SY-5609 in patients with select solid tumors in the first quarter of 2020.
Aug 06, 2019 04:01 pm ET
Syros to Present at 2019 Wedbush PacGrow Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference. Details are as follows:
Aug 01, 2019 07:31 am ET
Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2019, and provided an update on recent accomplishments and upcoming events.
Jul 25, 2019 08:30 am ET
Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 1, 2019 to report its second quarter 2019 financial results and provide a corporate update.
Jun 12, 2019 08:31 am ET
Syros Announces Appointment of Alice T. Shaw to its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Alice Tsang Shaw, M.D., Ph.D., to the Company’s Board of Directors. Dr. Shaw is a highly respected oncologist and recognized leader in translational medicine and the development of targeted cancer therapies.
Jun 12, 2019 08:01 am ET
Syros to Present at JMP Securities Life Sciences Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Details are as follows:
May 07, 2019 08:31 am ET
New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the online publication of a new manuscript, Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7, in the American Association for Cancer Research’s (AACR) journal, Cancer Research. SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being investigated in a Phase 1 clinical trial as a single agent and in combination with stan
May 01, 2019 07:30 am ET
Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2019 and provided an update on recent accomplishments and upcoming events.
Apr 24, 2019 08:01 am ET
Syros to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 1, 2019 to report its first quarter 2019 financial results and provide a corporate update.
Apr 17, 2019 08:01 am ET
Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunities for selective cyclin-dependent kinase 7 (CDK7) inhibition in ovarian and breast cancers on Wednesday, April 24, 2019 from 8:30 – 10:30 a.m. ET in New York City. Syros is currently evaluating SY-1365, a first-in-class selective CDK7 inhibitor, in a Phase 1 clinical trial as a single agent
Apr 09, 2019 04:01 pm ET
Syros Announces Closing of Concurrent Public Offerings
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its previously announced concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to 1,951,844 shares of its common stock, at a combined price to the public of $7.50 per common share and accompanying Class A warrant and (ii) 666 shares of its Series A convertible preferred stock, which are convertible into 666,000 shares
Apr 08, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Advanced Micro Devices, Syros Pharmaceuticals, La Jolla Pharmaceutical, Integer, Mesoblast, and InnerWorkings — What Drives Growth in Today's Competitive La
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Advanced Micro Devices, Inc. (NASDAQ:AMD), Syros Pharmaceuticals, Inc....
Apr 05, 2019 07:15 am ET
Syros Announces Pricing of $70 Million Concurrent Public Offerings
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has priced its concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to 1,951,844 shares of its common stock, at a combined price to the public of $7.50 per common share and accompanying Class A warrant and (ii) 666 shares of its Series A convertible preferred stock, which are convertible into 666,000 shares of its common stock,
Apr 04, 2019 04:18 pm ET
Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, (i) shares of its common stock and Class A warrants to purchase common stock, and (ii) shares of its Series A convertible preferred stock and Class A warrants to purchase common stock, in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not conti
Apr 02, 2019 04:01 pm ET
Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today presented new preclinical data across its franchise of selective cyclin-dependent kinase 7 (CDK7) inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta. New data on SY-1365, a first-in-class selective CDK7 inhibitor currently in a Phase 1 clinical trial, suggest that RB pathway alterations are predictive of response in preclinical models of high-grade ovarian cancer (HGOC) and support th
Mar 07, 2019 07:30 am ET
Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on recent accomplishments and upcoming events.
Mar 06, 2019 08:31 am ET
Syros to Participate in Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences.
Feb 28, 2019 08:30 am ET
Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 7, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update.
Feb 27, 2019 04:31 pm ET
Syros to Present New Preclinical Data on Its Selective CDK7 Inhibitors, SY-1365 and SY-5609, at AACR Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research (AACR) Annual Meeting taking place March 29-April 3 in
Feb 05, 2019 08:20 am ET
Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Re
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ArcBest Corporation (NASDAQ:ARCB), International Game Technology...
Jan 06, 2019 05:00 pm ET
Syros Announces Strategic Priorities and Expected Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones. The Company will review these priorities in a presentation at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 9:00 a.m. PST (12:00 p.m. EST).
Jan 03, 2019 08:01 am ET
Syros to Present at 37th Annual J.P. Morgan Healthcare Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2019 objectives, at the 37th Annual J.P. Morgan Healthcare Conference. Details are as follows:
Dec 21, 2018 08:01 am ET
Syros Added to NASDAQ Biotechnology Index
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 24th, 2018.
Dec 07, 2018 08:01 am ET
Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, showing that it inhibits tumor cell growth in hormone receptor-positive (HR-positive) breast cancer cell lines that are resistant to treatment with CDK4/6 inhibitors and that it has synergistic activity in combination with fulvestrant in these treatment-resistant cells. These data are being presented by
Dec 02, 2018 12:01 pm ET
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced initial clinical data from cohorts in its ongoing Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine and with daratumumab in genomically defined patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS). These data are being presented at the 60th American Society of Hematology (ASH)
Nov 30, 2018 08:30 am ET
Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store — Emerging Consolidated Expectations, Ana
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Gartner, Inc. (NYSE:IT), CONVERGEONE HLD (NASDAQ:CVON), Syros...
Nov 20, 2018 08:01 am ET
Syros to Present at 30th Annual Piper Jaffray Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference. Details are as follows:
Nov 15, 2018 09:30 am ET
Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors. These data, the first clinical data reported on a selective CDK7 inhibitor, were highlighted in an oral plenary session at the 30th EORTC-NCI-AACR Molecular Targets an
Nov 13, 2018 07:01 am ET
Syros Presents New Preclinical Combination Data on SY-1365 and First Preclinical Data from Oral CDK7 Inhibitor Program at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, showing synergistic anti-tumor activity in combination with carboplatin, a standard-of-care therapy, in models of ovarian cancer and providing a mechanistic rationale for the ongoing investigation of the combination in the Phase 1 clinical trial of SY-1365. The Company also announced the first preclinical da
Nov 09, 2018 04:01 pm ET
Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, will be featured in a Spotlight poster discussion session at the San Antonio Breast Cancer Symposium taking place December 4-8 in San Antonio. The data show that SY-1365 has dose-dependent inhibitory activity in hormone receptor-positive breast cancer cell lines that are resistant to treatment with
Nov 01, 2018 09:01 am ET
Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present initial clinical data from both combination cohorts in its ongoing Phase 2 trial of SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking
Nov 01, 2018 07:00 am ET
Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2018 and provided an update on recent accomplishments and upcoming events.
Oct 30, 2018 07:01 am ET
Syros to Present Clinical and Preclinical Data on SY-1365 and Earlier-Stage Pipeline at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in advanced solid tumor patients in an oral plenary session at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium taking place November 13-16 in Dublin. The presentation will include data on safety, pharmacok
Oct 25, 2018 07:30 am ET
Syros to Report Third Quarter 2018 Financial Results on Thursday, November 1, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial results and provide a corporate update.
Oct 23, 2018 08:50 am ET
Market Trends Toward New Normal in Syros Pharmaceuticals, Westlake Chemical Partners LP, SITO Mobile, ShotSpotter, Motorcar Parts of America, and Benefitfocus — Emerging Consolidated Expectations, Ana
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), Westlake Chemical Partners...
Sep 26, 2018 07:31 am ET
Syros to Present at 2018 Cantor Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2018 Cantor Global Healthcare Conference. Details are as follows:
Sep 06, 2018 08:01 am ET
Syros to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference. Details are as follows:
Aug 29, 2018 07:30 am ET
Report: Developing Opportunities within Cree, ArcBest, Syros Pharmaceuticals, Aegion, Adecoagro S.A, and Nevsun Resources — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cree, Inc. (NASDAQ:CREE), ArcBest Corporation (NASDAQ:ARCB), Syros...
Aug 08, 2018 08:01 am ET
Syros to Present at 2018 Wedbush PacGrow Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Financial Officer Joseph J. Ferra will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference. Details are as follows:
Aug 07, 2018 07:30 am ET
Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today reported financial results for the quarter ended June 30, 2018 and provided an update on recent accomplishments and upcoming events.
Jul 31, 2018 08:01 am ET
Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to report its second quarter 2018 financial results and provide a corporate update.
Jul 26, 2018 08:00 am ET
Investor Expectations to Drive Momentum within ShotSpotter, Kohl's, Cheniere Energy Partners LP, Palo Alto Networks, Syros Pharmaceuticals, and Ryman Hospitality Properties — Discovering Underlying Fa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ShotSpotter Inc. (NASDAQ:SSTI), Kohl's Corporation (NYSE:KSS), Cheniere...
Jul 10, 2018 08:01 am ET
Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunity for new combination approaches
Jun 14, 2018 04:01 pm ET
Syros Announces Appointment of Michael W. Bonney to Its Board of Directors
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Michael W. Bonney to the Company’s Board of Directors. Mr. Bonney brings extensive strategic, operational, commercial and leadership experience in the b
May 30, 2018 08:01 am ET
Syros to Present at Upcoming Investor Conferences
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences. Details are as follows:
May 21, 2018 08:20 am ET
Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group N.V, HCI Group, Tennant, and Ebix — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), J J Snack Foods Corp....
May 16, 2018 05:01 pm ET
Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company will present on the design of its Phase 1 clinical trial of SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor,
May 10, 2018 07:30 am ET
Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today reported financial results for the quarter ended March 31, 2018 and provided an update on recent accomplishments and upcoming events.
May 03, 2018 08:01 am ET
Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 10, 2018 to report its first quarter 2018 financial results and provide
Apr 16, 2018 08:01 am ET
Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced new preclinical data showing that SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 trial in patients w
Mar 26, 2018 08:30 am ET
Report: Developing Opportunities within AllianceBernstein Holding, Deutsche Bank Aktiengesellschaft, Syros Pharmaceuticals, Ply Gem, Ensco plc, and Berkshire Hills — Future Expectations, Projections M
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AllianceBernstein Holding L.P. (NYSE:AB), Deutsche Bank...
Mar 14, 2018 04:30 pm ET
Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company and its collaborators from the Dana-Farber Cancer Institute will present new preclinical data on SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 trial in patients with advanced solid tumors, at the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-18, 2018 in Chicago.
Mar 12, 2018 07:15 am ET
Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today reported financial results for the fourth quarter and year ended December 31, 2017 and provided an update on recent accomplishments and planned upcoming events.
Mar 12, 2018 07:00 am ET
Syros Announces Appointment of Joseph J. Ferra as Chief Financial Officer
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Joseph J. Ferra as the Company’s Chief Financial Officer. Mr. Ferra brings significant financial, strategic and leadership experience in the biotechnology industry.
Mar 05, 2018 08:32 am ET
Syros to Present at Upcoming Investor Conferences
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences. Details are as follows:
Feb 08, 2018 08:01 am ET
Syros to Present at Leerink Partners 7th Annual Global Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference. Details are as follows:
Feb 07, 2018 04:01 pm ET
Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 628,272 shares at the public offering price of $9.55 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Syros to 4,816,753 shares and
Jan 30, 2018 08:59 pm ET
Syros Announces Pricing of $40 Million Public Offering of Common Stock
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that it has priced an underwritten public offering of 4,188,481 shares of common stock at a price to the public of $9.55 per share, before underwriting discounts and commissions, which would result in aggregate gross proceeds of approximately $40.0 million. Syros has also granted the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offer
Jan 30, 2018 04:01 pm ET
Syros Announces Proposed Offering of Common Stock
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, $40.0 million of its common stock in an underwritten public offering. Syros also intends to grant the underwriters a 30-day option to purchase up to $6.0 million of its common stock at the public offering price, less underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund
Jan 22, 2018 08:01 am ET
Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that the U.S. Patent and Trademark Office has issued two patents covering methods for stratifying patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) for treatment with SY-1425 (tamibarotene), the Company’s first-in-class selective retinoic acid receptor alpha (RARα) agonist.
Jan 08, 2018 08:01 am ET
Syros Announces 2018 Strategic Priorities and Expected Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today outlined its strategic plan and expected milestones for 2018. In a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 10:30 a.m. PST (1:30 p.m. EST), the Company will detail its three strategic priorities for the year:
Jan 08, 2018 08:00 am ET
Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. Incyte will have exc
Jan 04, 2018 08:01 am ET
Syros to Present at 36th Annual J.P. Morgan Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2018 objectives, at the 36th Annual J.P. Morgan Healthcare Conference. Details are as follows:
Jan 02, 2018 08:01 am ET
Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARα Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that it has entered into a clinical supply agreement with Janssen Research and Development, LLC. Under the agreement, Janssen will supply daratumumab for a recently added combination dosing cohort in Syros’ ongoing Phase 2 clinical trial of SY-1425, a first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute
Dec 10, 2017 09:01 am ET
Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced initial clinical data from its ongoing Phase 2 trial of SY-1425, its first-in-class oral, selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The data are being presented at the 59th American Society of Hematology (ASH) Annual Meeting a
Dec 10, 2017 09:01 am ET
Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, show anti-tumor activity in in vitro and in vivo models of blood cancers. Additionally, the data point to a potential biomarker of response to SY-1365 and synergistic a
Dec 07, 2017 08:01 am ET
Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer S
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response. The Company also announced its identificati
Nov 21, 2017 08:01 am ET
Syros to Present at 29th Annual Piper Jaffray Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference. Details are as follows:
Nov 14, 2017 07:00 am ET
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Torque, an immuno-oncology company developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor microenvironment, today announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering. The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the "ho...
Nov 13, 2017 04:01 pm ET
Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present new preclinical data identifying potential biomarkers predictive of response to SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, at the San Antonio Breast Cancer Symposium (SABCS) taking place December 5-9 in San Antonio. The Comp
Nov 13, 2017 08:01 am ET
Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced the appointment of industry veteran Jeremy P. Springhorn, Ph.D., as Chief Business Officer. Dr. Springhorn will hold broad management responsibility for business development and strategic planning.
Nov 08, 2017 08:01 am ET
Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today reported financial results for the quarter ended September 30, 2017 and provided an update on recent accomplishments and upcoming events.
Nov 01, 2017 09:01 am ET
Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that initial clinical data from the ongoing Phase 2 trial of SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7)
Oct 30, 2017 08:01 am ET
Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that new preclinical pharmacodynamic (PD) and pharmacokinetic (PK) data providing a rationale for the twice weekly dosing regimen currently being used in the ongoing Phase 1 clinical trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in advanced solid tumors were presented at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer T
Oct 26, 2017 08:01 am ET
Syros’ Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that it has identified alterations in regulatory regions of the genome in immune, tumor and stromal cells isolated from pancreatic cancer patient tumors, leading to the identification of new drug targets. These findings, which were made as part of a research collaboration with the Lowy laboratory at the University of California San Diego (UCSD) Moores Cancer Center, were
Oct 20, 2017 04:01 pm ET
Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company’s drug discovery research in immuno-oncology will be highlighted in an oral presentation at the American College of Surgeons (ACS) 2017 Clinical Congress taking place October 22-26 in San Diego.
Oct 16, 2017 04:01 pm ET
Syros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present preclinical pharmacokinetic (PK) and pharmacodynamic (PD) data on SY-1365, its first-in-class selective cyclin-depe
Oct 05, 2017 08:01 am ET
Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the biomarker status of patients screened for the ongoing Phase 2 clinical trial of SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), was predictive of myeloid cell differentiation in the patients’ blood sa
Dec 15, 2016 12:01 am ET
Flagship Ventures Evolves Name To Flagship Pioneering
CAMBRIDGE, Mass., Dec. 15, 2016 /PRNewswire/ -- As Flagship Ventures enters its 17th year, the firm announced today that it is changing its name to Flagship Pioneering. Flagship's evolved name reflects the distinctive nature of its enterprise: systematically conceiving, creating, resourcing and growing first-in-category ventures to transform human health and sustainability. The announcement comes as the firm closed an innovative, follow-on capital pool, capping a year of unprecedented achievements.  The $285 million Special Opportunities Fund operates alongside Flagship's most recent early-s...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.